AYTU BIOPHARMA Business Summary

Aytu BioPharma, Inc. (AYTU) is a specialty pharmaceutical company that generates revenue through the commercialization of prescription therapeutics, primarily focusing on central nervous system (CNS) and pediatric conditions. The company’s revenue model is driven by product sales across three primary segments: the ADHD Portfolio (featuring Adzenys XR-ODT® and Cotempla XR-ODT®), the Pediatric Portfolio (including Karbinal® ER and Poly-Vi-Flor®), and its newly launched psychiatry centerpiece, EXXUA™ (gepirone ER). Launched in late 2025, EXXUA represents Aytu's entry into the multi-billion dollar Major Depressive Disorder market, shifting the company's strategic focus toward high-margin psychiatric treatments. Aytu competes directly with specialty firms like Tris Pharma and Ironshore Pharmaceuticals in the ADHD space, while positioning itself against larger CNS-focused peers such as Axsome Therapeutics and Intra-Cellular Therapies in the antidepressant market. Aytu was co-founded in 2015 by brothers Joshua R. Disbrow and Jarrett Disbrow, who previously built Arbor Pharmaceuticals from inception to a successful nine-figure exit. CEO Joshua Disbrow, formerly COO of Ampio Pharmaceuticals and a veteran of LipoScience and GlaxoSmithKline, leads the company alongside Chief Business Officer Jarrett Disbrow, the former CEO of Vyrix Pharmaceuticals. The leadership team includes CFO Ryan Selhorn, a CPA with a background at Grant Thornton and Innovus Pharmaceuticals, and Chief Commercial Officer Greg Pyszczymuka, who joined via the 2021 Neos Therapeutics merger. The company is governed by a board chaired by John Donofrio, Jr., a senior industry executive appointed in late 2024, and features significant institutional oversight from directors like Abhinav Jain of Nantahala Capital Management, one of the company’s largest shareholders.